Glycemic Outcomes and Device Engagement Over 18 Months Following Initiation of Two Different Automated Insulin Delivery Systems in American Youth With Type 1 Diabetes [0.03%]
美国儿童1型糖尿病患者启动两种不同类型的自动胰岛素输送系统后长达18个月的血糖结局和设备依从性状况
Jayde Hooven-Davis,Ingrid Libman,Scott D Rothenberger et al.
Jayde Hooven-Davis et al.
Objective: We compared long-term, real-world glycemic outcomes and device engagement in U.S. youth with type 1 diabetes (T1D) using two automated insulin delivery (AID) systems. ...
Real-World Total Daily Insulin Dose in over 14,000 Young Individuals with Type 1 Diabetes in the United States [0.03%]
美国一万多名一型糖尿病青年人的实际每日总胰岛素剂量水平研究
Rebecca L Molinsky,Jason Gaglia,Yumin Zhang et al.
Rebecca L Molinsky et al.
Objective: Insulin requirements for people with type 1 diabetes (T1D) may vary with changes in age, pubertal status, and weight. There are limited data to assess insulin requirements based on age, sex, and body mass index...
Real-World Ketone Testing Patterns Among People Using FreeStyle Libre [0.03%]
使用FreeStyle Libre免费应用程序人群的酮体检测模式分析
Richard M Bergenstal,Naunihal Virdi,Farhan Quadri et al.
Richard M Bergenstal et al.
Objective: Ketone testing behavior in relation to glucose control is not well characterized. We aimed to describe ketone testing patterns and assess glucose control among individuals using a FreeStyle Libre (FSL) reader a...
Cardiovascular, Renal, and Hepatic Biomarkers Outside Guideline-Recommended Thresholds: Prevalence and Determinants in Type 1 Diabetes [0.03%]
1型糖尿病患者心、肾、肝标志物超出指南推荐界值的流行病学和影响因素研究
Jaime C Lucove,Emilee M Cornelius,Huyen T Nguyen et al.
Jaime C Lucove et al.
Introduction: The objective of the study was to evaluate the prevalence of cardiovascular, renal, and hepatic biomarkers that fall outside guideline-based thresholds in adults with type 1 diabetes (T1D), and to identify d...
Real-World Impact of a National Funding-Driven Transition Between Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes [0.03%]
国家资助驱动的儿科1型糖尿病患者自动胰岛素输送系统转换的现实世界影响
Max Walker,Amal Thomas,Hannah Allison et al.
Max Walker et al.
In October 2024, New Zealand's pharmaceutical funding agency (PHARMAC) introduced fully funded access to Tandem t:slim X2 and Ypsomed YpsoPump insulin pumps, alongside Abbott and Dexcom continuous glucose monitoring (CGM). As Medtronic CGM ...
Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes [0.03%]
MiniMed™ 780G高级混合闭环系统使用超速效赖脯胰岛素在儿童和成人1型糖尿病患者中的安全性和有效性：AACE/CDS糖尿病综合护理标准2022
Halis K Akturk,Laura M Nally,Rayhan A Lal et al.
Halis K Akturk et al.
Background: Given the faster onset and shorter duration of action of ultra-rapid insulin lispro-aabc (URLi, Lyumjev™ insulin), compared with insulin lispro (a rapid-acting insulin [RAI]), the present study investigated t...
Operational and Clinical Insights from a Fully Decentralized Clinical Study Evaluating Protocol Adherence, Participant Satisfaction, and Connected Device Data in Individuals with Type 2 Diabetes on Different Treatment Regimens [0.03%]
一种新型去中心化临床研究的操作和临床见解——评估不同治疗方案的2型糖尿病患者的依从性、患者满意度和连接设备数据
Kirsten Nørgaard,Uffe Christian Braae,Anne Kaas et al.
Kirsten Nørgaard et al.
Objective: Traditional clinical trials place a substantial burden on participants owing to the need for frequent, tightly controlled site visits, which can limit access and participation. Advances in digital health allow ...
Continuous Glucose Monitoring in Insulin-Treated Type 2 Diabetes Mellitus in Sweden: A Scoping Review and Policy Landscape Analysis [0.03%]
瑞典胰岛素治疗的2型糖尿病患者的持续葡萄糖监测：系统评价和政策环境分析
Johan Jendle,Peter Adolfsson,Jarl Hellman et al.
Johan Jendle et al.
Background: Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases in Sweden. Continuous glucose monitoring (CGM) is an increasingly important alternative to self-monitoring of blood glucose (SMBG), pa...
MiniMed™ 780G System Users Achieve Similar Glycemic Outcomes Regardless of Socioeconomic Disadvantage [0.03%]
MiniMed™ 780G系统使用者的血糖结局不受社会经济不利因素的影响
Margaret Liu,Fang Niu,Caroline Yovanovich et al.
Margaret Liu et al.
Socioeconomic disadvantage, as measured by the Area Deprivation Index (ADI), is associated with health disparities in diabetes management. This real-world analysis evaluated glycemic outcomes among United States users of the MiniMed™ 780G ...